Tag: CTIS

Figure Standards That Stick: Labels, Ordering, Color Rules

Posted on digi By digi

Figure Standards That Stick: Labels, Ordering, Color Rules Figure Standards That Stick: Making Labels, Ordering, and Color Rules Reproducible and Reviewer-Friendly Why “figure standards” are a regulatory deliverable—not just a style preference Figures drive first impressions and hard questions For many reviewers, your figures are the first contact with the analysis, so they must answer…

Read More “Figure Standards That Stick: Labels, Ordering, Color Rules” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy

Posted on digi By digi

Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy Bridging Foreign Data into a US IND: An Inspection-Ready Strategy for Acceptability, Traceability, and Real-World Timelines Why bridging foreign data is a speed lever—and how to make it acceptable the first time Start with the regulatory outcome, then design the bridge For many sponsors, the…

Read More “Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy” »

US Regulatory Submissions

TLF Shells That Align Teams: Templates, Titles, Footnotes

Posted on digi By digi

TLF Shells That Align Teams: Templates, Titles, Footnotes TLF Shells That Align Teams: How to Design Templates, Titles, and Footnotes Everyone Can Defend Outcome-first TLF shells: align science, statistics, and inspection in one artifact What the shell must prove on Day 1 Well-made TLF shells do three jobs simultaneously: they communicate analysis intent to programmers…

Read More “TLF Shells That Align Teams: Templates, Titles, Footnotes” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

IND on a Budget—What Not to Cut (Small Sponsor Tactics)

Posted on digi By digi

IND on a Budget—What Not to Cut (Small Sponsor Tactics) IND on a Budget—Smart Cuts, Not Blind Cuts: Small-Sponsor Tactics that Preserve Speed and Reviewability Outcome-Oriented Budgeting: Buy Time, De-Risk Holds, and Keep Your First-Patient-In Date Define the decision gates before you cut a dollar Lean programs win by funding decisions, not documents. Before trimming,…

Read More “IND on a Budget—What Not to Cut (Small Sponsor Tactics)” »

US Regulatory Submissions

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships

Posted on digi By digi

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships Rare-Disease Enrollment Playbook: Managing Windows, Building Support, and Structuring Partnerships That Actually Deliver Why rare-disease enrollment is different—and the operating model that makes it predictable What breaks in “business-as-usual” enrollment for rare conditions In rare diseases, enrollment fails for structural reasons: low prevalence spread across wide geographies, heterogeneous diagnostic…

Read More “Rare-Disease Enrollment Playbook: Windows, Support, Partnerships” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice

Posted on digi By digi

US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice Early Advice Pathways Compared: Getting Actionable FDA Meeting Outcomes vs EMA Scientific Advice (with UK/Global Notes) Why early advice determines your development velocity—and how to aim for decisionable outcomes Begin with a decision map, not a calendar Whether you pursue US or EU first,…

Read More “US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice” »

US Regulatory Submissions

Right-First-Time IND Cover Letters & Cross-References (US-First)

Posted on digi By digi

Right-First-Time IND Cover Letters & Cross-References (US-First) Right-First-Time IND Cover Letters and Cross-Reference Strategy: A US-First, Inspection-Ready Playbook Why the IND cover letter is your speed lever—and how to write one that gets triaged fast Start with decisions, not descriptions The best IND cover letters are not courtesies; they are decision memos disguised as letters….

Read More “Right-First-Time IND Cover Letters & Cross-References (US-First)” »

US Regulatory Submissions

Investigator Meeting Content Map: Drive Screen Quality Day-1

Posted on digi By digi

Investigator Meeting Content Map: Drive Screen Quality Day-1 Investigator Meeting Content Map to Drive Day-1 Screening Quality (and Keep It Inspection-Ready) What an Investigator Meeting must deliver: reproducible screen quality from the very first patient The outcome we’re buying with an IM The point of an Investigator Meeting (IM) is not inspiration—it is repeatable performance….

Read More “Investigator Meeting Content Map: Drive Screen Quality Day-1” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Type A/B/C Meetings: Questions That Get Actionable FDA Feedback

Posted on digi By digi

Type A/B/C Meetings: Questions That Get Actionable FDA Feedback Type A/B/C Meetings: Crafting Questions That Get Actionable FDA Feedback the First Time Outcome-first framing: the fastest path to “clear, actionable” answers Start with the decision you want, then write backwards Every successful Agency interaction starts with a decision list: what you want the review team…

Read More “Type A/B/C Meetings: Questions That Get Actionable FDA Feedback” »

US Regulatory Submissions

Country Mix Optimization: Add Sites with Predictable Gains

Posted on digi By digi

Country Mix Optimization: Add Sites with Predictable Gains Country Mix Optimization: How to Add Sites That Deliver Predictable Gains (Not Just More Complexity) Outcome-first site expansion: when adding countries lifts velocity—and when it only adds noise The real question: will a new country raise weekly randomizations with confidence? “Add more sites” is a reflex; “add…

Read More “Country Mix Optimization: Add Sites with Predictable Gains” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment